Horizon Therapeutics plc products

A humanized, affinity-optimized, afucosylated IgG1 kappa (IgG1κ) monoclonal antibody (mAb) that binds to the B cell-specific surface antigen CD19.

A fusion protein binding CD40L on T cells, blocking their interaction with CD40-expressing B cells. We are investigating dazodalibep in focal segmental glomerulosclerosis as well as conducting Phase 2 trials in kidney transplant rejection, rheumatoid arthritis and Sjögren’s syndrome.

A fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus erythematosus.

A monoclonal antibody against insulin-like growth factor-1 receptor (IGF-1R). TED in Japan (OPTIC-J): Phase 3 randomized, placebo-controlled trial in Japan to evaluate TEPEZZA in patients with moderate-to-severe active TED.

A fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. We are conducting a Phase 1 trial in autoimmune diseases.

Collaboration and option agreement with Q32 Bio to develop ADX-914, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune pathways.

Exclusive collaboration to develop novel, multi-specific fusion protein based therapies for autoimmune and inflammatory diseases.

Exclusive collaboration to investigate a short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase in the liver (GalNAc) to reduce serum uric acid and treat uncontrolled gout.

Exclusive collaboration to discover new therapeutics for novel gout targets by combining HemoShear’s discovery expertise with Horizon’s rheumatology development and commercialization expertise.